Narrow your search

Library

FARO (1)

KU Leuven (1)

LUCA School of Arts (1)

Odisee (1)

Thomas More Kempen (1)

Thomas More Mechelen (1)

UCLL (1)

ULiège (1)

VIVES (1)

Vlaams Parlement (1)


Resource type

book (2)


Language

English (2)


Year
From To Submit

2022 (2)

Listing 1 - 2 of 2
Sort by

Book
Advances and Novel Treatment Options in Metastatic Melanoma
Authors: --- ---
Year: 2022 Publisher: Basel MDPI - Multidisciplinary Digital Publishing Institute

Loading...
Export citation

Choose an application

Bookmark

Abstract

The book presents several studies reporting advances on melanoma pathogenesis, diagnosis and therapy. It represents a milestone on the state of the art, updated at 2021, and also presents the current knowledge on the future developments in melanoma field.

Keywords

Medicine --- melanoma --- invasion --- WNT5A --- MARCKS --- phosphorylation --- MANS peptide --- nanoparticles --- cell therapy --- tumor microenvironment --- sex/gender --- sex-hormones --- immunity --- microRNAs --- immunotherapy --- BRAF-mutant melanoma --- BRAF inhibitor --- mechanism of action --- targeted therapy --- tumour microenvironment --- plasmacytoid dendritic cells --- lactate dehydrogenase --- TLR --- interferon --- CXCL10 --- TPC2 --- HIPPO --- SOCE --- metastasis --- essential oils --- angiogenesis --- apoptosis --- uveal melanoma (UM) --- metastatic uveal melanoma (mUM) --- prognostication --- adjuvant therapy --- metastatic therapy --- metastatic dormancy --- liver-directed-therapies --- targeted-therapy --- combined therapy --- protein tyrosine phosphatase --- PTPs inhibitors --- melanoma immune infiltrate --- BRAF inhibitors --- microenvironment --- resistance --- therapy --- therapeutic resistance --- exosomes --- extracellular vesicles --- diagnosis --- prognosis --- ctDNA --- liquid biopsy --- prediction --- patient stratification --- BRAF --- arthralgia --- rheumatoid arthritis --- carbonic anhydrase --- hedgehog --- cyclopamine --- small molecules --- acetazolamide --- motility --- metalloproteinases --- FAK --- cancer --- mucosal melanoma --- nivolumab --- pembrolizumab --- ipilimumab --- radiotherapy --- cholinergic system --- acetylcholine --- muscarinic receptors --- nicotinic receptors --- melanoma metastasis --- ShcD adaptor protein --- amoeboid motility --- Rac1 --- DOCK4 --- melanoma PDX --- target therapy --- cancer stem cells --- slow cycling phenotype --- drug resistance --- OXPHOS --- lipid metabolism --- cancer associated fibroblast --- melanomagenesis --- biomarkers --- checkpoint inhibitor --- PD-1 --- melanoma markers --- cytokines --- machine learning --- Support Vector Machine --- principal component analysis --- BCL2L10 --- STAT3 --- cytotoxicity --- survival --- ABT-737 --- Bcl-2 family --- ML258 --- HuR --- MITF --- metastases --- siRNA --- melanoma --- invasion --- WNT5A --- MARCKS --- phosphorylation --- MANS peptide --- nanoparticles --- cell therapy --- tumor microenvironment --- sex/gender --- sex-hormones --- immunity --- microRNAs --- immunotherapy --- BRAF-mutant melanoma --- BRAF inhibitor --- mechanism of action --- targeted therapy --- tumour microenvironment --- plasmacytoid dendritic cells --- lactate dehydrogenase --- TLR --- interferon --- CXCL10 --- TPC2 --- HIPPO --- SOCE --- metastasis --- essential oils --- angiogenesis --- apoptosis --- uveal melanoma (UM) --- metastatic uveal melanoma (mUM) --- prognostication --- adjuvant therapy --- metastatic therapy --- metastatic dormancy --- liver-directed-therapies --- targeted-therapy --- combined therapy --- protein tyrosine phosphatase --- PTPs inhibitors --- melanoma immune infiltrate --- BRAF inhibitors --- microenvironment --- resistance --- therapy --- therapeutic resistance --- exosomes --- extracellular vesicles --- diagnosis --- prognosis --- ctDNA --- liquid biopsy --- prediction --- patient stratification --- BRAF --- arthralgia --- rheumatoid arthritis --- carbonic anhydrase --- hedgehog --- cyclopamine --- small molecules --- acetazolamide --- motility --- metalloproteinases --- FAK --- cancer --- mucosal melanoma --- nivolumab --- pembrolizumab --- ipilimumab --- radiotherapy --- cholinergic system --- acetylcholine --- muscarinic receptors --- nicotinic receptors --- melanoma metastasis --- ShcD adaptor protein --- amoeboid motility --- Rac1 --- DOCK4 --- melanoma PDX --- target therapy --- cancer stem cells --- slow cycling phenotype --- drug resistance --- OXPHOS --- lipid metabolism --- cancer associated fibroblast --- melanomagenesis --- biomarkers --- checkpoint inhibitor --- PD-1 --- melanoma markers --- cytokines --- machine learning --- Support Vector Machine --- principal component analysis --- BCL2L10 --- STAT3 --- cytotoxicity --- survival --- ABT-737 --- Bcl-2 family --- ML258 --- HuR --- MITF --- metastases --- siRNA


Book
Advances and Novel Treatment Options in Metastatic Melanoma
Authors: --- ---
Year: 2022 Publisher: Basel MDPI - Multidisciplinary Digital Publishing Institute

Loading...
Export citation

Choose an application

Bookmark

Abstract

The book presents several studies reporting advances on melanoma pathogenesis, diagnosis and therapy. It represents a milestone on the state of the art, updated at 2021, and also presents the current knowledge on the future developments in melanoma field.

Keywords

melanoma --- invasion --- WNT5A --- MARCKS --- phosphorylation --- MANS peptide --- nanoparticles --- cell therapy --- tumor microenvironment --- sex/gender --- sex-hormones --- immunity --- microRNAs --- immunotherapy --- BRAF-mutant melanoma --- BRAF inhibitor --- mechanism of action --- targeted therapy --- tumour microenvironment --- plasmacytoid dendritic cells --- lactate dehydrogenase --- TLR --- interferon --- CXCL10 --- TPC2 --- HIPPO --- SOCE --- metastasis --- essential oils --- angiogenesis --- apoptosis --- uveal melanoma (UM) --- metastatic uveal melanoma (mUM) --- prognostication --- adjuvant therapy --- metastatic therapy --- metastatic dormancy --- liver-directed-therapies --- targeted-therapy --- combined therapy --- protein tyrosine phosphatase --- PTPs inhibitors --- melanoma immune infiltrate --- BRAF inhibitors --- microenvironment --- resistance --- therapy --- therapeutic resistance --- exosomes --- extracellular vesicles --- diagnosis --- prognosis --- ctDNA --- liquid biopsy --- prediction --- patient stratification --- BRAF --- arthralgia --- rheumatoid arthritis --- carbonic anhydrase --- hedgehog --- cyclopamine --- small molecules --- acetazolamide --- motility --- metalloproteinases --- FAK --- cancer --- mucosal melanoma --- nivolumab --- pembrolizumab --- ipilimumab --- radiotherapy --- cholinergic system --- acetylcholine --- muscarinic receptors --- nicotinic receptors --- melanoma metastasis --- ShcD adaptor protein --- amoeboid motility --- Rac1 --- DOCK4 --- melanoma PDX --- target therapy --- cancer stem cells --- slow cycling phenotype --- drug resistance --- OXPHOS --- lipid metabolism --- cancer associated fibroblast --- melanomagenesis --- biomarkers --- checkpoint inhibitor --- PD-1 --- melanoma markers --- cytokines --- machine learning --- Support Vector Machine --- principal component analysis --- BCL2L10 --- STAT3 --- cytotoxicity --- survival --- ABT-737 --- Bcl-2 family --- ML258 --- HuR --- MITF --- metastases --- siRNA --- n/a

Listing 1 - 2 of 2
Sort by